Biopharma Partnerships And Injectable Demand Will Expand Global Reach

Published
26 Jan 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$10.00
24.0% undervalued intrinsic discount
14 Aug
US$7.60
Loading
1Y
26.7%
7D
3.1%

Author's Valuation

US$10.0

24.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 42%

Shared on23 Apr 25
Fair value Decreased 29%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget has increased revenue growth from 5.1% to 12.6% and decreased future PE multiple from 29.2x to 23.6x.

Shared on09 Apr 25
Fair value Increased 0.40%

AnalystConsensusTarget has decreased revenue growth from 8.1% to 5.1% and increased future PE multiple from 26.3x to 29.2x.

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 1.20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 1.21%

Shared on11 Mar 25
Fair value Decreased 1.20%

AnalystConsensusTarget has decreased revenue growth from 10.9% to 8.1%, increased future PE multiple from 23.0x to 26.4x and decreased shares outstanding growth rate from 0.2% to 0.1%.